Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Recs

5
Player Avatar zzlangerhans (99.70) Submitted: 10/20/2011 6:03:02 PM : Outperform Start Price: $3.53 FOLD Score: +79.07

The great Amicus run of 2010-2011 is now a thing of the past, with the share price having returned to the early 2010 level of 3.4. At the peak, the stock was up 300% from the lows although the only positive catalyst was a rather unimpressive partnership deal for Amigal with Glaxo. The share price is now plunging with a string of late stage trial results for Amigal expected over the next year. The first of these, a phase II trial of Amigal co-administered with enzyme replacement, will likely provide results before the end of 2011. The more critical results of the first phase III trial of Amigal alone in Fabry's disease will likely not be available until mid-2012.

Amicus stock could drop back to the 2010 lows of 2 with renewed broad market decline, but is also in a position to rebound with encouraging phase II data later this year. I've had success with Amicus as a GBMB stock before, so this seems an opportune time to create a green thumb reference point.

Featured Broker Partners


Advertisement